Genotoxicity, In-Vivo, RNA and Trials - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Genotoxicity

In-Vivo

RNA

Trials

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

MARCH 8, 2021

This program included assays such as Big Blue and PIG-a designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo. The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems. “We

Trials

Trials In-Vivo Genotoxicity RNA

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

MAY 10, 2023

This stage is more highly regulated and consists of both preclinical testing and clinical trials. Until recently, drug carcinogenicity assessment required two different in vivo studies, one of which was typically a two-year lifetime study in rats. Drug discovery and development is an arduous process that can cost upwards of $2.6

Bioassay

Bioassay Genotoxicity Drugs In-Vivo

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Accelerating NDA filing through faster carcinogenicity assessment

Stay Connected